GlaxoSmithKline Plc’s 2 Greatest Strengths

Two standout factors supporting an investment in GlaxoSmithKline plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I think of pharmaceutical company GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), two factors jump out at me as the firm’s greatest strengths and top the list of what makes the company  attractive as an investment proposition.

1. Turnaround potential

Overall, GlaxoSmithKline’s revenue figures were flat in 2012 and in 2013, and look like being flat again in 2014. The embattled pharmaceutical giant has been up against a tidal wave of generic competition in all markets, which drives selling prices down.  Older products that time-out on exclusivity are often best-sellers and stalwarts of the firm’s revenue and cash flow generation. So, it’s no surprise that the financial figures have been suffering. However, even drugs under patent protection face competition from other producers’ alternatives. On top of that, revenue has collapsed in China, where the company is under the regulatory spotlight for misconduct.

Such lacklustre financial performance has driven Glaxo into refocusing on core activities and cost cutting, and the CEO reckons that 2013 was a good year for research and development (R&D). So, the firm is fighting back and, going forward, new product launches could re-ignite growth. City analysts following the firm expect earnings to grow by about 8% during 2015.

As the firm focuses on launching its new pipeline, it is also selling off non-core assets and parts of the business capable of realising shareholder value. For example, the recently announced sale of the Lucozade and Ribena brands to Suntory and the sale of Arixtra and Fraxiparine, for a combined £2.05 billion return. Such moves keep the cash flowing, which makes me optimistic about continuing dividend progression. The forward dividend yield is running around 5.2%, which isn’t a bad return for patient investors prepared to give Glaxo the benefit of the doubt about its future turnaround and return to growth.

2. Consumable products

The great thing about Glaxo’s products is that they fall under the category of Consumables: people buy them, use them up, and buy them again, over and over. Such characteristics can lead to consistent and predictable cash flow, which is great for supporting a dividend payment policy. There’s an added bonus with pharmaceuticals, though: unlike washing-up liquid or similar consumables, people rarely skip a repeat- purchase because, say, the budget is a bit tight. When people need medicines, they need them.

Such rock-solid repeat-purchase credentials are why investors flock to the pharmaceutical companies for steady dividend income. With the prospect of growth returning, the shares are all the more attractive.

What now?

GlaxoSmithKline’s turnaround potential combines with its cash-generating credentials to create an interesting investment proposition.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin does not own any GlaxoSmithKline shares. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »

Investing Articles

AI stocks vs EV shares; which is the best sector for me to invest in?

Jon Smith considers the recent rally in AI stocks and weighs up whether to allocate more money there versus EV…

Read more »

A graph made of neon tubes in a room
Investing Articles

Do Greggs shares have even more growth ahead?

Greggs shares have seen some solid growth in the last few months, as the economy shows positive signs. But is…

Read more »

Investing For Beginners

How I’d aim to grow my Stocks & Shares ISA from £20k to £1m

Jon Smith explains how diversification and focusing on sectors for the future can help grow his Stocks and Shares ISA.

Read more »